Effect of virtual reality-based biofeedback for depressive and anxiety symptoms: Randomized controlled study.

BACKGROUND: The use of virtual reality (VR)-based biofeedback (BF), a relatively new intervention, is a non-pharmacological treatment of depressive and anxiety symptoms. However, studies on VR-based BF are lacking and inconclusive. METHODS: A total of 131 adults were recruited from the community. Participants who scored ≥10 on the Patient Health Questionnaire-9 (PHQ-9) or ≥ 9 on the Panic Disorder Severity Scale (PDSS) were included in the group with depressive or anxiety symptoms (DAS group), and others as the healthy control group (HC group). Participants from the DAS group were randomly assigned to VR-based or conventional BF intervention. All individuals visited at three times (weeks 0, 2, and 4), and completed the Montgomery-Asberg Depression Rating Scale (MADRS), the State-Trait Anxiety Inventory (STAI), and a visual analog scale (VAS) before and after the intervention, and PHQ-9 at the beginning and final visit. RESULTS: The analysis included a total of 118 participants (DAS/VR: 40, DAS/BF: 38, HC/VR: 40). There was no significant difference in demographic variables among the three groups. After the intervention, the DAS/VR and the DAS/BF groups exhibited significant decreases in MADRS, PHQ-9, STAI, and VAS scores compared to the baseline of each group (p < 0.005). There were no significant differences between the effects of VR-based BF and conventional BF. The HC group also showed significant decreases in the measures of depression and anxiety after receiving VR-based BF. CONCLUSION: VR-based BF was effective in reducing depressive and anxiety symptoms, even for subthreshold depression and anxiety symptoms in the HC group.

A study on the functional near-infrared spectroscopy on impaired prefrontal activation and impulsivity during cognitive task in patients with major depressive disorder.

BACKGROUND: This study aimed to examine the association between prefrontal activation during a verbal fluency task (VFT) and impulsivity among patients with major depressive disorder (MDD), using functional near-infrared spectroscopy (fNIRS). METHODS: We enrolled a total of 119 participants, 60 with MDD patients and 59 with healthy controls (HCs), aged 18 to 34 years. The Barratt Impulsiveness Scale-11 (BIS-11) was used to assess impulsivity after completing baseline demographic, clinical, and physical assessments. A VFT was used to examine prefrontal activation during cognitive executions while fNIRS was monitored. The changing values of oxygenated hemoglobin (oxy-Hb) and their associations with the BIS-11 score were analyzed. RESULTS: The data analysis comprised 109 participants in total (54 MDD; 55 HCs). Spearman's correlation analysis of the MDD group showed a negative correlation between changes in oxy-Hb and BIS-11 values in the right prefrontal cortex, notably the right frontopolar cortex (FPC) and ventromedial prefrontal cortex (VMPFC). After adjusting for sex, age, years of education, and Hamilton Depression Rating Scale (HAMD), significance was maintained in the right FPC [ρ = -0.317, p = 0.027], and the right VMPFC [ρ = -0.327, p = 0.022]. Furthermore, multivariate linear regression suggested a significant association in the right prefrontal cortex with BIS-11 score [ß = -1.904, SE = 0.799, p = 0.0214]. CONCLUSIONS: Impaired prefrontal activation during a verbal fluency task, led to higher impulsivity in patients with MDD.